Oncologists explore the opportunity of CAR T-cell therapy for the treatment of relapsed/refractory multiple myeloma.
EP. 2: Healthcare Utilization for Relapsed/Refractory MM PatientsJanuary 11th 2021
Drs Deepu Madduri and Parameswaran Hari explain the high rates of use of healthcare resources in relapsed/refractory multiple myeloma and recommend strategies that may reduce resource utilization and treatment variability.
EP. 5: CAR T-Cell Therapy in Relapsed/Refractory MMJanuary 18th 2021
Parameswaran Hari, MD, MRCP, of the Medical College of Wisconsin, comments on the rationale for studying CAR T-cell therapy as a treatment option for relapsed/refractory multiple myeloma and the discusses the role of more recent data in supporting cost and coverage decisions by payers.